MX2022015813A - 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. - Google Patents
2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.Info
- Publication number
- MX2022015813A MX2022015813A MX2022015813A MX2022015813A MX2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A
- Authority
- MX
- Mexico
- Prior art keywords
- mcl
- inhibitors
- enamides
- macrocyclic
- fluoro
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- HCXHLLLLCRZPES-UHFFFAOYSA-N C=C(C(C(N)=O)N)F Chemical class C=C(C(C(N)=O)N)F HCXHLLLLCRZPES-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con agentes farmacéuticos útiles para terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos (Fórmula (I)) y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20179237 | 2020-06-10 | ||
PCT/EP2021/065483 WO2021250102A1 (en) | 2020-06-10 | 2021-06-09 | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015813A true MX2022015813A (es) | 2023-01-24 |
Family
ID=71083532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015813A MX2022015813A (es) | 2020-06-10 | 2021-06-09 | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230219906A1 (es) |
EP (1) | EP4165050A1 (es) |
JP (1) | JP2023528965A (es) |
KR (1) | KR20230023008A (es) |
CN (1) | CN115698023A (es) |
AU (1) | AU2021288987A1 (es) |
BR (1) | BR112022025117A2 (es) |
CA (1) | CA3180387A1 (es) |
MX (1) | MX2022015813A (es) |
WO (1) | WO2021250102A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6899975B2 (ja) | 2018-05-14 | 2021-07-07 | ギリアード サイエンシーズ, インコーポレイテッド | Mcl−1阻害剤 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
JP7441947B2 (ja) | 2019-11-26 | 2024-03-01 | ギリアード サイエンシーズ, インコーポレイテッド | Mcl1阻害剤を調製するためのプロセス及び中間体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
EP3668878A1 (en) * | 2017-08-18 | 2020-06-24 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
US11279712B2 (en) * | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
EP3762393B1 (en) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists |
JP6899975B2 (ja) | 2018-05-14 | 2021-07-07 | ギリアード サイエンシーズ, インコーポレイテッド | Mcl−1阻害剤 |
MA54157A (fr) * | 2018-11-09 | 2021-09-15 | Prelude Therapeutics Inc | Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1) |
EP3771469A1 (en) | 2019-07-30 | 2021-02-03 | Amgen, Inc | Formulations and dosages for administering a compound that inhibits mcl1 protein |
-
2021
- 2021-06-09 EP EP21731492.1A patent/EP4165050A1/en active Pending
- 2021-06-09 JP JP2022575939A patent/JP2023528965A/ja active Pending
- 2021-06-09 CA CA3180387A patent/CA3180387A1/en active Pending
- 2021-06-09 MX MX2022015813A patent/MX2022015813A/es unknown
- 2021-06-09 KR KR1020237001116A patent/KR20230023008A/ko active Search and Examination
- 2021-06-09 CN CN202180041672.5A patent/CN115698023A/zh active Pending
- 2021-06-09 BR BR112022025117A patent/BR112022025117A2/pt unknown
- 2021-06-09 US US18/000,439 patent/US20230219906A1/en active Pending
- 2021-06-09 WO PCT/EP2021/065483 patent/WO2021250102A1/en active Application Filing
- 2021-06-09 AU AU2021288987A patent/AU2021288987A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021288987A1 (en) | 2023-02-09 |
WO2021250102A1 (en) | 2021-12-16 |
CA3180387A1 (en) | 2021-12-16 |
KR20230023008A (ko) | 2023-02-16 |
CN115698023A (zh) | 2023-02-03 |
BR112022025117A2 (pt) | 2022-12-27 |
US20230219906A1 (en) | 2023-07-13 |
EP4165050A1 (en) | 2023-04-19 |
JP2023528965A (ja) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA522433087B1 (ar) | Sos1 مثبطات | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
MX2023007192A (es) | Inhibidores de prmt5. | |
MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
MX2023000438A (es) | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. | |
MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
MX2020006219A (es) | Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer. | |
PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. | |
MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
MX2023007297A (es) | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. | |
MX2024005928A (es) | 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
MX2022015005A (es) | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. | |
MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
MX2022010299A (es) | Derivados macrocíclicos de indol como inhibidores de mcl-1. | |
MX2022011565A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2023007291A (es) | Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1. | |
MX2022016004A (es) | Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. | |
MX2022015998A (es) | Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1. |